Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Wilson MR, Gutierrez B, Offord S, Blanchette CM, Eramo A, Earnshaw SR, Kamat SA. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs Context. 2016 Mar 11;5:212273. doi: 10.7573/dic.212273
Bernfort L, Brodtkorb T. QALY som effektmått inom vården : möjligheter och begränsningar. Linköping: linköping University Electronic Press. Cmt- Rapport. 2012.
Brodtkorb T. National system for assessment, prioritization and introduction of non-pharmaceutical health technologies, a pilot study. Cmt- Rapport. 2010.